表紙
市場調查報告書

鐮形血球貧血症:開發中產品分析

Sickle Cell Disease - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 213124
出版日期 內容資訊 英文 271 Pages
訂單完成後即時交付
價格
鐮形血球貧血症:開發中產品分析 Sickle Cell Disease - Pipeline Review, H1 2020
出版日期: 2020年04月30日內容資訊: 英文 271 Pages
簡介

鐮狀細胞貧血症為遺傳性(先天性)的血液疾病,血液中的紅血球形狀異常。主要的前兆、症狀為貧血和發育遲緩、視野障礙、疼痛、頻繁感染感染疾病等。主要的治療方法,有抗生素和止痛藥、輸血、幹細胞移植等。

本報告提供全球各國治療鐮形血球貧血症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

鐮形血球貧血症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

鐮形血球貧血症:企業開發中的治療藥

鐮形血球貧血症:大學/機關研究中的治療藥

鐮形血球貧血症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

鐮形血球貧血症:企業開發中的產品

鐮形血球貧血症:大學/機關研究中的產品

鐮形血球貧血症的治療藥開發企業

  • Acceleron Pharma, Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Addex Therapeutics Ltd
  • Advinus Therapeutics Ltd.
  • Alnylam Pharmaceuticals, Inc.
  • BioAegis Therapeutics, Inc.
  • Bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Complexa, Inc.
  • CSL Limited
  • Dilaforette AB
  • Editas Medicine, Inc.
  • Emmaus Medical, Inc.
  • Errant Gene Therapeutics, LLC
  • Gamida Cell Ltd.
  • Gilead Sciences, Inc.
  • Global Blood Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • La Jolla Pharmaceutical Company
  • Merck & Co., Inc.
  • Morphogenesis, Inc.
  • NKT Therapeutics, Inc.
  • Novartis AG
  • Orphagen Pharmaceuticals, Inc.
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • Prolong Pharmaceuticals, LLC
  • ReveraGen BioPharma, Inc.
  • Sancilio & Company, Inc.
  • Sangamo BioSciences, Inc.
  • Sanofi

鐮形血球貧血症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

鐮形血球貧血症:最近的開發平台趨勢

鐮形血球貧血症:暫停中的計劃

鐮形血球貧血症:開發中止的產品

鐮形血球貧血症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12134IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sickle Cell Disease - Pipeline Review, H1 2020, provides an overview of the Sickle Cell Disease (Hematological Disorders) pipeline landscape.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sickle Cell Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 9, 11, 4, 26 and 8 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 1 molecules, respectively.

Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
    • Sickle Cell Disease - Overview
    • Sickle Cell Disease - Therapeutics Development
    • Sickle Cell Disease - Therapeutics Assessment
    • Sickle Cell Disease - Companies Involved in Therapeutics Development
    • Sickle Cell Disease - Drug Profiles
    • Sickle Cell Disease - Dormant Projects
    • Sickle Cell Disease - Discontinued Products
    • Sickle Cell Disease - Product Development Milestones
    • Appendix

    List of Tables

    • Number of Products under Development for Sickle Cell Disease, H1 2020
    • Number of Products under Development by Companies, H1 2020
    • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
    • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
    • Number of Products under Development by Universities/Institutes, H1 2020
    • Products under Development by Companies, H1 2020
    • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
    • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
    • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
    • Products under Development by Universities/Institutes, H1 2020
    • Number of Products by Stage and Target, H1 2020
    • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
    • Number of Products by Stage and Mechanism of Action, H1 2020
    • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
    • Number of Products by Stage and Route of Administration, H1 2020
    • Number of Products by Stage and Molecule Type, H1 2020
    • Sickle Cell Disease - Pipeline by Agios Pharmaceuticals Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Alkermes Plc, H1 2020
    • Sickle Cell Disease - Pipeline by Angiocrine Bioscience Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Annexin Pharmaceuticals AB, H1 2020
    • Sickle Cell Disease - Pipeline by Aruvant Sciences Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Axcella Health Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Beam Therapeutics Inc, H1 2020
    • Sickle Cell Disease - Pipeline by bluebird bio Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co, H1 2020
    • Sickle Cell Disease - Pipeline by C4X Discovery Holdings Plc, H1 2020
    • Sickle Cell Disease - Pipeline by Cannabis Science Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Cell Source Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Cetya Therapeutics Inc, H1 2020
    • Sickle Cell Disease - Pipeline by CRISPR Therapeutics AG, H1 2020
    • Sickle Cell Disease - Pipeline by CSL Ltd, H1 2020
    • Sickle Cell Disease - Pipeline by Cyclerion Therapeutics Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Dystrogen Therapeutics SA, H1 2020
    • Sickle Cell Disease - Pipeline by Editas Medicine Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Emmaus Life Sciences Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Epidestiny Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Epizyme Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Errant Gene Therapeutics LLC, H1 2020
    • Sickle Cell Disease - Pipeline by ExCellThera Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Forma Therapeutics Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Fulcrum Therapeutics Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Functional Fluidics LLC, H1 2020
    • Sickle Cell Disease - Pipeline by Gamida Cell Ltd, H1 2020
    • Sickle Cell Disease - Pipeline by Gilead Sciences Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Glycan Therapeutics Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Hillhurst Biopharmaceuticals Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Homology Medicines Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Imara Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Intellia Therapeutics Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Invenux LLC, H1 2020
    • Sickle Cell Disease - Pipeline by Medeor Therapeutics Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Merck & Co Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Micelle BioPharma Inc, H1 2020
    • Sickle Cell Disease - Pipeline by MimeTech Srl, H1 2020
    • Sickle Cell Disease - Pipeline by Modus Therapeutics AB, H1 2020
    • Sickle Cell Disease - Pipeline by Molecules For Health Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Novartis AG, H1 2020
    • Sickle Cell Disease - Pipeline by Oryzon Genomics SA, H1 2020
    • Sickle Cell Disease - Pipeline by PHD Biosciences, H1 2020
    • Sickle Cell Disease - Pipeline by Phoenicia Biosciences Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Rare Partners Srl, H1 2020
    • Sickle Cell Disease - Pipeline by Regenacy Pharmaceuticals LLC, H1 2020
    • Sickle Cell Disease - Pipeline by ReNeuroGen LLC, H1 2020
    • Sickle Cell Disease - Pipeline by Sangamo Therapeutics Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Secura Bio Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Syros Pharmaceuticals Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Tarus Therapeutics Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Trucode Gene Repair Inc, H1 2020
    • Sickle Cell Disease - Pipeline by Vanguard Therapeutics Inc, H1 2020
    • Sickle Cell Disease - Dormant Projects, H1 2020
    • Sickle Cell Disease - Dormant Projects, H1 2020 (Contd..1), H1 2020
    • Sickle Cell Disease - Dormant Projects, H1 2020 (Contd..2), H1 2020
    • Sickle Cell Disease - Dormant Projects, H1 2020 (Contd..3), H1 2020
    • Sickle Cell Disease - Discontinued Products, H1 2020

    List of Figures

    • Number of Products under Development for Sickle Cell Disease, H1 2020
    • Number of Products under Development by Companies, H1 2020
    • Number of Products under Development by Universities/Institutes, H1 2020
    • Number of Products by Top 10 Targets, H1 2020
    • Number of Products by Stage and Top 10 Targets, H1 2020
    • Number of Products by Top 10 Mechanism of Actions, H1 2020
    • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
    • Number of Products by Routes of Administration, H1 2020
    • Number of Products by Stage and Routes of Administration, H1 2020
    • Number of Products by Top 10 Molecule Types, H1 2020
    • Number of Products by Stage and Top 10 Molecule Types, H1 2020